Recursion Pharmaceuticals Inc.
Clinical trials sponsored by Recursion Pharmaceuticals Inc., explained in plain language.
-
New hope for FAP patients: early trial targets dangerous polyps
Disease control Recruiting nowThis early-stage trial is testing an oral drug called REC-4881 in adults with Familial Adenomatous Polyposis (FAP), a genetic condition that causes many polyps and a high cancer risk. The study aims to see if the drug is safe, how it behaves in the body, and if it can reduce the …
Phase: PHASE1, PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New pill tested for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called REC-1245 for people with advanced cancers that have spread or cannot be removed by surgery. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help shr…
Phase: PHASE1, PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC